RNA Deep Sequencing Analysis Reveals That Nicotine Restores Impaired Gene Expression by Viral Proteins in the Brains of HIV-1 Transgenic Rats

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Cao, Junran ^a   Wang, Shaolin ^a   Wang, Ju ^a,b   Cui, Wenyan ^a,c   Nesil, Tanseli ^a   Vigorito, Michael ^d   Chang, Sulie L ^d   Li, Ming D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d SETON HALL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALCIUM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPHRIN B; GLUTATHIONE; MEMBRANE PROTEIN; NICOTINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CALCIUM SIGNALING; CITRIC ACID CYCLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; GENE EXPRESSION; GLUTATHIONE METABOLISM; HIPPOCAMPUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PREFRONTAL CORTEX; RAT; RNA SEQUENCE; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; BRAIN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIPPOCAMPUS; HIV-1; MALE; NICOTINE; NICOTINIC AGONISTS; PREFRONTAL CORTEX; RATS; RATS, TRANSGENIC; SEQUENCE ANALYSIS, RNA; VIRAL PROTEINS;

EID: 84880463714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068517     Document Type: Article

References (86)

1. Wiley CA, Soontornniyomkij V, Radhakrishnan L, Masliah E, Mellors J, et al. (1998) Distribution of brain HIV load in AIDS. Brain Pathol 8: 277-284.
2. Krebs FC, Ross H, McAllister J, Wigdahl B, (2000) HIV-1-associated central nervous system dysfunction. Adv Pharmacol 49: 315-385.
3. Del Valle L, Pina-Oviedo S, (2006) HIV disorders of the brain: pathology and pathogenesis. Front Biosci 11: 718-732.
4. Xu J, Ikezu T, (2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol 4: 200-212.
5. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, et al. (2003) Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 9: 205-221.
6. Gonzalez-Scarano F, Martin-Garcia J, (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81.
7. Vigano A, Trabattoni D, Schneider L, Ottaviani F, Aliffi A, et al. (2006) Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. J Pediatr 148: 389-391.
8. Jones LE, Perelson AS, (2005) Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol 67: 1227-1251.
9. Lucas S, (2001) Update on the pathology of AIDS. Intensive Crit Care Nurs 17: 155-166.
10. Sleasman JW, Goodenow MM, (2003) 13. HIV-1 infection. Journal of Allergy and Clinical Immunology 111: 582-592.
11. Agbottah E, Zhang N, Dadgar S, Pumfery A, Wade JD, et al. (2006) Inhibition of HIV-1 virus replication using small soluble Tat peptides. Virology 345: 373-389.
12. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT, (2005) Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11: 1805-1843.
13. Gianotti N, Lazzarin A, (2005) Sequencing antiretroviral drugs for long-lasting suppression of HIV replication. New Microbiol 28: 281-297.
14. Reid W, Sadowska M, Denaro F, Rao S, Foulke J Jr, et al. (2001) An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 98: 9271-9276.
15. Lashomb AL, Vigorito M, Chang SL, (2009) Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J Neurovirol 15: 14-24.
16. Vigorito M, LaShomb AL, Chang SL, (2007) Spatial learning and memory in HIV-1 transgenic rats. J Neuroimmune Pharmacol 2: 319-328.
17. Homji NF, Mao X, Langsdorf EF, Chang SL, (2012) Endotoxin-induced cytokine and chemokine expression in the HIV-1 transgenic rat. J Neuroinflammation 9: 3.
18. Midde NM, Gomez AM, Harrod SB, Zhu J, (2011) Genetically expressed HIV-1 viral proteins attenuate nicotine-induced behavioral sensitization and alter mesocorticolimbic ERK and CREB signaling in rats. Pharmacol Biochem Behav 98: 587-597.
19. Sarkar S, Mao X, Liu C, Chang SL (2012) Age- and Ethanol Concentration-Dependent Effects of Acute Binge Drinking in the HIV-1 Transgenic Rat. Alcohol Clin Exp Res.
20. Furey ML, (2011) The prominent role of stimulus processing: cholinergic function and dysfunction in cognition. Curr Opin Neurol 24: 364-370.
21. Pepeu G, Giovannini MG, (2010) Cholinesterase inhibitors and memory. Chem Biol Interact 187: 403-408.
22. Swan GE, Lessov-Schlaggar CN, (2007) The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev 17: 259-273.
23. Sellin AK, Shad M, Tamminga C, (2008) Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr 13: 985-996.
24. Hernandez CM, Dineley KT, (2012) alpha7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both? Curr Drug Targets 13: 613-622.
25. Bartus RT, (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163: 495-529.
26. Picciotto MR, Zoli M, (2002) Nicotinic receptors in aging and dementia. J Neurobiol 53: 641-655.
27. Riljak V, Langmeier M, (2005) Nicotine an efficient tool of the neurobiological research today, the tool of treatment tomorrow? Prague Med Rep 106: 329-348.
28. Mihailescu S, Drucker-Colin R, (2000) Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 31: 131-144.
29. Lee PN, (1994) Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 13: 131-144.
30. Cataldo JK, Prochaska JJ, Glantz SA, (2010) Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 19: 465-480.
31. Pauly JR, Charriez CM, Guseva MV, Scheff SW, (2004) Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Ann N Y Acad Sci 1035: 316-334.
32. Sopori M, (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2: 372-377.
33. Sopori ML, Kozak W, (1998) Immunomodulatory effects of cigarette smoke. J Neuroimmunol 83: 148-156.
34. De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L, (2005) Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2: 4.
35. Sharifzadeh M, Tavasoli M, Naghdi N, Ghanbari A, Amini M, et al. (2005) Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats. J Neurochem 95: 1078-1090.
36. Bracci L, Lozzi L, Rustici M, Neri P, (1992) Binding of HIV-1 gp120 to the nicotinic receptor. FEBS Lett 311: 115-118.
37. Farr SA, Banks WA, Uezu K, Freed EO, Kumar VB, et al. (2002) Mechanisms of HIV type 1-induced cognitive impairment: evidence for hippocampal cholinergic involvement with overstimulation of the VIPergic system by the viral coat protein core. AIDS Res Hum Retroviruses 18: 1189-1195.
38. Loram LC, Harrison JA, Chao L, Taylor FR, Reddy A, et al. (2010) Intrathecal injection of an alpha seven nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in rats. Brain Behav Immun 24: 959-967.
39. Rock RB, Gekker G, Aravalli RN, Hu S, Sheng WS, et al. (2008) Potentiation of HIV-1 expression in microglial cells by nicotine: involvement of transforming growth factor-beta 1. J Neuroimmune Pharmacol 3: 143-149.
40. Abbud RA, Finegan CK, Guay LA, Rich EA, (1995) Enhanced production of human immunodeficiency virus type 1 by in vitro-infected alveolar macrophages from otherwise healthy cigarette smokers. J Infect Dis 172: 859-863.
41. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, et al. (2004) Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull 64: 165-170.
42. Gonzalez-Lira B, Rueda-Orozco PE, Galicia O, Montes-Rodriguez CJ, Guzman K, et al. (2006) Nicotine prevents HIVgp120-caused electrophysiological and motor disturbances in rats. Neurosci Lett 394: 136-139.
43. Vigorito M, Cao J, Li MD, Chang SL (2013) Acquisition and long-term retention of spiral learning in HIV-1 transgenic and F344 rats: effects of repeated nicotine treatment. J NeuroVirilogy Accepted.
44. Paxinos G, Watson C (1998) The Rat Brain in Stereotaxic Coordinates. New York: Academic Press.
45. Li MD, Cao J, Wang S, Wang J, Sarkar S, et al. (2013) Transcriptome sequencing of gene expression in the brain of the HIV-1 transgenic rat. PLoS One 8(3): e59582.
46. Li MD, Kane JK, Wang J, Ma JZ, (2004) Time-dependent changes in transcriptional profiles within five rat brain regions in response to nicotine treatment. Brain Res Mol Brain Res 132: 168-180.
47. Wei J, Wang J, Dwyer JB, Mangold J, Cao J, et al. (2011) Gestational nicotine treatment modulates cell death/survival-related pathways in the brains of adolescent female rats. Int J Neuropsychopharmacol 14: 91-106.
48. Cao J, Dwyer JB, Mangold JE, Wang J, Wei J, et al. (2011) Modulation of cell adhesion systems by prenatal nicotine exposure in limbic brain regions of adolescent female rats. Int J Neuropsychopharmacol 14: 157-174.
49. Cui WY, Wang J, Wei J, Cao J, Chang SL, et al. (2012) Modulation of innate immune-related pathways in nicotine-treated SH-SY5Y cells. Amino Acids 43: 1157-1169.
50. Leslie FM, Mojica CY, Reynaga DD, (2013) Nicotinic receptors in addiction pathways. Mol Pharmacol 83: 753-758.
51. Tuesta LM, Fowler CD, Kenny PJ, (2011) Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol 82: 984-995.
52. Clevers H, Nusse R, (2012) Wnt/beta-catenin signaling and disease. Cell 149: 1192-1205.
53. Huang JY, Hong YT, Chuang JI, (2009) Fibroblast growth factor 9 prevents MPP+-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro. J Neurochem 109: 1400-1412.
54. Toledo EM, Colombres M, Inestrosa NC, (2008) Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 86: 281-296.
55. Inestrosa NC, Toledo EM, (2008) The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. Mol Neurodegener 3: 9.
56. Tawk M, Makoukji J, Belle M, Fonte C, Trousson A, et al. (2011) Wnt/beta-catenin signaling is an essential and direct driver of myelin gene expression and myelinogenesis. J Neurosci 31: 3729-3742.
57. Nave KA, Trapp BD, (2008) Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 31: 535-561.
58. Schmidbauer M, Huemer M, Cristina S, Trabattoni GR, Budka H, (1992) Morphological spectrum, distribution and clinical correlation of white matter lesions in AIDS brains. Neuropathol Appl Neurobiol 18: 489-501.
59. Berger JR, Tornatore C, Major EO, Bruce J, Shapshak P, et al. (1992) Relapsing and remitting human immunodeficiency virus-associated leukoencephalomyelopathy. Ann Neurol 31: 34-38.
60. Li MD, Cao J, Wang S, Wang J, Sarkar S, et al. (2013) Transcriptome Sequencing of Gene Expression in the Brain of the HIV-1 Transgenic Rat. PLoS One 8: e59582.
61. Montcouquiol M, Crenshaw EB 3rd, Kelley MW (2006) Noncanonical Wnt signaling and neural polarity. Annu Rev Neurosci 29: 363-386.
62. Varela-Nallar L, Alfaro IE, Serrano FG, Parodi J, Inestrosa NC, (2010) Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses. Proc Natl Acad Sci U S A 107: 21164-21169.
63. Farias GG, Alfaro IE, Cerpa W, Grabowski CP, Godoy JA, et al. (2009) Wnt-5a/JNK signaling promotes the clustering of PSD-95 in hippocampal neurons. J Biol Chem 284: 15857-15866.
64. Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, et al. (2000) EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 103: 945-956.
65. Grunwald IC, Korte M, Wolfer D, Wilkinson GA, Unsicker K, et al. (2001) Kinase-independent requirement of EphB2 receptors in hippocampal synaptic plasticity. Neuron 32: 1027-1040.
66. Henderson JT, Georgiou J, Jia Z, Robertson J, Elowe S, et al. (2001) The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron 32: 1041-1056.
67. Takasu MA, Dalva MB, Zigmond RE, Greenberg ME, (2002) Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science 295: 491-495.
68. Kennedy NJ, Martin G, Ehrhardt AG, Cavanagh-Kyros J, Kuan CY, et al. (2007) Requirement of JIP scaffold proteins for NMDA-mediated signal transduction. Genes Dev 21: 2336-2346.
69. Gilmartin MR, Helmstetter FJ, (2010) Trace and contextual fear conditioning require neural activity and NMDA receptor-dependent transmission in the medial prefrontal cortex. Learn Mem 17: 289-296.
70. Deisseroth K, Heist EK, Tsien RW, (1998) Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons. Nature 392: 198-202.
71. Dieterich DC, Karpova A, Mikhaylova M, Zdobnova I, Konig I, et al. (2008) Caldendrin-Jacob: a protein liaison that couples NMDA receptor signalling to the nucleus. PLoS Biol 6: e34.
72. Herve D, Levi-Strauss M, Marey-Semper I, Verney C, Tassin JP, et al. (1993) G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase. J Neurosci 13: 2237-2248.
73. Jones DT, Masters SB, Bourne HR, Reed RR, (1990) Biochemical characterization of three stimulatory GTP-binding proteins. The large and small forms of Gs and the olfactory-specific G-protein, Golf. J Biol Chem 265: 2671-2676.
74. Ohira K, Hayashi M, (2009) A new aspect of the TrkB signaling pathway in neural plasticity. Curr Neuropharmacol 7: 276-285.
75. Bito H, Takemoto-Kimura S, (2003) Ca(2+)/CREB/CBP-dependent gene regulation: a shared mechanism critical in long-term synaptic plasticity and neuronal survival. Cell Calcium 34: 425-430.
76. Lonze BE, Ginty DD, (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35: 605-623.
77. Meister A, (1988) Glutathione metabolism and its selective modification. J Biol Chem 263: 17205-17208.
78. Schulz JB, Lindenau J, Seyfried J, Dichgans J, (2000) Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 267: 4904-4911.
79. Pocernich CB, Butterfield DA, (2012) Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 1822: 625-630.
80. Martin HL, Teismann P, (2009) Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 23: 3263-3272.
81. Phillis JW, O'Regan MH, (2004) A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. Brain Res Brain Res Rev 44: 13-47.
82. Yu JW, Shi Y, (2008) FLIP and the death effector domain family. Oncogene 27: 6216-6227.
83. Ballester LY, Capo-Velez CM, Garcia-Beltran WF, Ramos FM, Vazquez-Rosa E, et al. (2012) Up-regulation of the neuronal nicotinic receptor alpha7 by HIV glycoprotein 120: potential implications for HIV-associated neurocognitive disorder. J Biol Chem 287: 3079-3086.
84. Feligioni M, Raiteri L, Pattarini R, Grilli M, Bruzzone S, et al. (2003) The human immunodeficiency virus-1 protein Tat and its discrete fragments evoke selective release of acetylcholine from human and rat cerebrocortical terminals through species-specific mechanisms. J Neurosci 23: 6810-6818.
85. Ciardo A, Meldolesi J, (1993) Effects of the HIV-1 envelope glycoprotein gp120 in cerebellar cultures. [Ca2+]i increases in a glial cell subpopulation. Eur J Neurosci 5: 1711-1718.
86. Jiang D, Zhao L, Clapham DE, (2009) Genome-wide RNAi screen identifies Letm1 as a mitochondrial Ca2+/H+ antiporter. Science 326: 144-147.